Ascendis Pharma Undercuts 50-Day Line After Pricing Fiasco Prompts Guidance Cut
Ascendis Pharma stock tumbled Wednesday after the firm cut its outlook for its human growth hormone amid marketwide price struggles. The post Ascendis Pharma Undercuts 50-Day Line After Pricing Fiasco Prompts Guidance Cut appeared first on Investor's Business Daily.
Ascendis Pharma stock tumbled Wednesday after the firm cut its outlook for its human growth hormone amid marketwide price struggles.
The post Ascendis Pharma Undercuts 50-Day Line After Pricing Fiasco Prompts Guidance Cut appeared first on Investor's Business Daily.
iShook Opinion
"iShook Opinion" by Beni E Rachmanov, CEO & Founder of iShook. Explore captivating perspectives on entertainment, lifestyle, and sports at ishookdaily.com. Your go-to for engaging insights.
